Stocks Health care NAGE
NASDAQ · Health careNiagen Bioscience, Inc. (NAGE)
Niagen Bioscience, Inc. brought in $122.3M of revenue over the twelve months to September 30, 2026, down 1.9% from a year earlier. Net income was $10.2M, a net margin of 8.4%. At September 30, 2026 it held $69.5M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 4, 2026.
Key facts about Niagen Bioscience, Inc.
- Net worth
- Niagen Bioscience, Inc. has a market value (market cap) of $170.1M at the latest share price, and shareholders' equity of $83.1M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $129.4M (+29.9% year on year), with net income of $17.4M. Over the 12 months to September 30, 2026: revenue $122.3M, net income $10.2M.
- Cash flow
- In fiscal 2025 operations brought in $13.5M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 4, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Niagen Bioscience, Inc.'s next report is expected around March 3, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Niagen Bioscience, Inc. does
Niagen Bioscience, Inc. is registered with the SEC under industry code SIC 2833 (Medicinal Chemicals & Botanical Products). Its shares trade on NASDAQ under the ticker NAGE.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $129.4M | $17.4M | $0.20 | n/a |
| 2024 | $99.6M | $8.6M | $0.11 | n/a |
| 2023 | $83.6M | -$4.9M | -$0.07 | n/a |
| 2022 | $72.1M | -$16.5M | -$0.24 | n/a |
| 2021 | $67.4M | -$27.1M | -$0.40 | n/a |
| 2020 | $59.3M | -$19.9M | -$0.33 | n/a |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where NAGE ranks in Health care
Latest SEC filings
What Niagen Bioscience, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 4, 2026Quarterly report 10-Q · period to September 30, 2026Revenue fell 20% to $27.2M versus the same quarter last year; diluted EPS -$0.01 versus $0.05.
- November 4, 2026
- August 4, 2026Quarterly report 10-Q · period to June 30, 2026Revenue fell 4.3% to $29.8M versus the same quarter last year; diluted EPS $0.01 versus $0.04.
- August 4, 2026
- July 29, 2026Passive stake (5% or more) SCHEDULE 13G
- June 29, 2026
- June 29, 2026
- May 6, 2026
- May 6, 2026Quarterly report 10-Q · period to March 31, 2026Revenue rose 3.3% to $31.5M versus the same quarter last year; diluted EPS $0.07 versus $0.06.
- April 29, 2026
Insider trades
What the people running Niagen Bioscience, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| June 30, 2026 | Fried Robert NChief Executive Officer, Director | Received as pay | 1,106 | $3K |
| June 30, 2026 | Pamir OzanChief Financial Officer | Received as pay | 4,255 | $11.5K |
| June 30, 2026 | Lopez Carlos LuisSVP, General Counsel | Received as pay | 2,314 | $6.3K |
| April 24, 2026 | Fried Robert NChief Executive Officer, Director | Exercised options | 20,000 | $52.2K |
| November 14, 2025 | Pamir OzanChief Financial Officer | Bought | 4,465 | $30.4K |
| November 14, 2025 | Pamir OzanChief Financial Officer | Boughtindirect | 2,220 | $15.2K |
Who owns NAGE
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
Largest institutional holders
Insiders
3 insiders reported holding 1,078,500 shares in total, about $2.3M at the last price.
| Holder | Shares |
|---|---|
| Fried Robert NChief Executive Officer, Director | 1,060,087 |
| Pamir OzanChief Financial Officer | 13,8482,220 held indirectly |
| Lopez Carlos LuisSVP, General Counsel | 4,565 |
Questions about NAGE
What does Niagen Bioscience, Inc. do?
Niagen Bioscience, Inc. is a company in the Health care sector, listed on NASDAQ as NAGE. Its shares trade on NASDAQ under the ticker NAGE.
What is Niagen Bioscience, Inc.'s net worth?
Niagen Bioscience, Inc. has a market value (market cap) of $170.1M at the latest share price, and shareholders' equity of $83.1M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Niagen Bioscience, Inc. profitable?
Yes. Over the twelve months to September 30, 2026 it reported net income of $10.2M on revenue of $122.3M, a net margin of 8.4%.
How much revenue does Niagen Bioscience, Inc. make?
Over the twelve months to September 30, 2026 Niagen Bioscience, Inc. reported revenue of $122.3M. That is 1.9% less than a year earlier.
When did Niagen Bioscience, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 4, 2026. It covers the period to September 30, 2026.
When is Niagen Bioscience, Inc.'s next earnings report?
Niagen Bioscience, Inc.'s next report is expected around March 3, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare NAGE with
Follow NAGE
Get an email when Niagen Bioscience, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Niagen Bioscience, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.